3. PCSK9 Mutations

4. PCSK9 Loss-of-function Mutations

5. 2013 ACC/AHA Cholesterol Guidelines 4 Major Statin Benefit Groups

7. PCSK9 Monoclonal Antibodies

8. MENDEL Evolocumab Monotherapy for Hypercholesterolemia

9. LAPLACE-2 Study Design

10. LAPLACE-2 LDL-C Response at Mean of Weeks 10 and 12

11. GAUSS-2 Percent Change in LDL-C From Baseline at Week 12 in Statin-Intolerant Patients

12. DESCARTES Percent Change in LDL-C From Baseline at Week 52 in Patients With Hypercholesterolemia

13. DESCARTES Evolocumab Safety at 52 weeks

14. PCSK9 CV OutcomesTrials

15. Abbreviations

16. Abbreviations (cont)

17. References

18. References (cont)

19. References (cont)